Posters

      Human Organotypic Nasal Epithelial Tissue Culture As An In Vitro Model To Evaluate Effects Of Cigarette Smoke Of A Candidate Modified Risk Tobacco Product: The Tobacco Heating System 2.2

      Mathis, C.; Cabanski, M.; Frentzel, S.; Kuehn, D.; Majeed, S.; Merg, C.; Elamin, A.; Guedj, E.; Dulize, R.; Peric, D.; Trivedi, K.; Benyagoub, A.; Xiang, Y.; Martin, F.; Leroy, P.; Ivanov, N. V.; Peitsch, M. C.; Hoeng, J.

      Conference date
      Feb 26, 2015
      Conference name
      Society for Research on Nicotine and Tobacco (SRNT) 2015
      Link to more information
      Link to more information
      Topic
      Summary

      Exposure to cigarette smoke (CS) is a major risk of developing serious diseases such as lung cancer, COPD or cardiovascular disease. The development of new tobacco products that could reduce such health impact is ongoing and requires a careful safety assessment strategy. To investigate the effect of the aerosol generated by Philip Morris International’s candidate Modified Risk Tobacco Product (MRTP), named Tobacco Heating System 2.2 (THS2.2), an in vitro model mimicking the human nasal epithelium was exposed for 28 min at the air-liquid interface to various doses. In parallel, exposure to fresh air (sham control) or to mainstream smoke from conventional cigarette (at doses where nicotine level within the aerosol are matching those of THS2.2 product) was performed. Various endpoints (cytotoxicity, CYP1A1/1B1 enzyme activity, inflammatory mediators release, morphological and transcriptomic changes) were collected at different times following exposure (4, 24, 48 and 72h) to identify and compare the dose- and time-dependent effect of each exposure conditions. By using systems toxicology-based risk assessment approaches combining computable biological network models and gene expression changes, we compared the molecular perturbations in both conventional combustible cigarettes and MRTP exposure conditions. While significant effect was quantified over different post-exposure time points in the networks representing cell death, inflammation, proliferation and cellular stress after CS exposure, the impact of THS2.2 exposure (at similar nicotine dose) was closer to sham controls and mostly limited at the earliest time point (4h). The results of all the additional endpoints measured during this study support a reduced impact of THS2.2 exposure on the nasal epithelial tissue culture compared to conventional CS. In conclusion, the side-by-side evaluation of the biological impact of comparable doses of THS2.2 aerosol and conventional CS shows a reduced exposure effect of this new tobacco product on human nasal epithelial tissue culture.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.